Switching from Zoledronic Acid to Denosumab for Bone Modification Therapy in Patients with Malignant Tumors and Renal Insufficiency: A Retrospective Case Series and Literature Review
Patients with abnormal renal function, BRCA1 mutations, or those at high risk of developing skeletal-related events may benefit from denosumab over zoledronic acid. During denosumab treatment in patients with renal dysfunction, attention should be paid to the occurrence of hypocalcemia.
Authors
- Xuezheng Wang (ORCID: https://orcid.org/0000-0002-8425-6294)
- Yan Xue (ORCID: https://orcid.org/0000-0003-1452-9522)
- Junmei Zhang (ORCID: https://orcid.org/0000-0002-1758-3674)
Institutions
- Columbia University Irving Medical Center (US)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1159/000548575
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05